| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 21.9 | 17.9 |
| Profit before tax | 4.6 | 2.2 |
| Net income | 4.0 | 2.4 |
| EPS (diluted, $ a share) | $0.05 | $0.03 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +68.2% |
|---|---|
| Revenue, year on year | +22.8% |
| Operating margin | 18.5% |
10-Q filed with the SEC, NYSE: PLX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Protalix BioTherapeutics, Inc.: key numbers
- Share price
- $3.03Close, Nov 16
- Market cap
- $255M
- Shares outstanding
- 84.32MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Protalix BioTherapeutics, Inc.
All →Protalix BioTherapeutics Financial Results
Protalix BioTherapeutics reported Q3 2026 financial results with total year-to-date revenues reaching $75.6 million, a significant increase from $43.6 million in the prior year. The company reported quarterly net income of $4.0 million and reaffirmed its full-year 2026 revenue guidance of $78.0 million to $83.0 million. Management highlighted the ongoing Phase 2 RELEASE study for PRX-115 in uncontrolled gout, with top-line results expected in the second half of 2027.
- Term
- Q3 2026
“We concluded the first nine months of 2026 with revenues of $75.6 million, reflecting our continued progress and growing financial strength which supports our ability to execute our strategy and advance our key priorities.”
Dror Bashan, President and Chief Executive Officer
“We end the quarter with cash and deposits of $48.5 million, a position of strength that enables us to continue advancing PRX-115 for uncontrolled gout. Uncontrolled gout is a disease with low quality of life and high unmet need and represents a blockbuster uricase market opportunity.”
Dror Bashan, President and Chief Executive Officer